Evidence map›Paper›PMID 42415804›Full record

ArticleFrontiers in medicine2026

Efficacy of Jishi Shuanghua Granules in preventing radiation-induced esophagitis in non-small cell lung cancer patients undergoing concurrent chemoradiotherapy: protocol for a multicenter, randomized, double-blind, placebo-controlled trial.

Huakang Li, Yuanzhen Mi, Ke Xu, Ming Fan, Jun Yin, Qiang Li, Ziliang Wu, Cuicui Gong, Yunjing Jia, Pengxuan Gu and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Huakang Li *School of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
Yuanzhen Mi *School of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
Ke Xu *Department of Radiation Oncology, Precision Radiation in Oncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China.
Ming Fan *Department of Radiation Oncology, Precision Radiation in Oncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China.
Jun Yin *Department of Radiation Oncology, Precision Radiation in Oncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China.
Qiang Li *Department of Medical Oncology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Ziliang WuSchool of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
Cuicui GongSchool of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
Yunjing JiaSchool of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
Pengxuan GuSchool of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
Shanshan WeiDepartment of Radiation Oncology, Precision Radiation in Oncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China.
Zhonglin ZhangDepartment of Radiation Oncology, Precision Radiation in Oncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China.
Shuo ZhangDepartment of Radiation Oncology, Precision Radiation in Oncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China.
Yuanyuan ZhengDivision of Internal Medicine, Department of Integrated Traditional Chinese and Western Medicine, Leshan City Shizhong District Cancer Hospital, Leshan, Sichuan, China.
Bing LinHealth Management Center, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Jinyi LangSchool of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
Biao ZhaoDepartment of Integrative Chinese and Western Medicine, Sichuan Cancer Center, Sichuan Cancer Hospital and Institute, Affiliated Cancer Hospital of the University of Electronic Science and Technology of China, Chengdu, China.
Meihua ChenDepartment of Radiation Oncology, Precision Radiation in Oncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Acute radiation-induced esophagitis (ARIE) is a common complication in non-small cell lung cancer (NSCLC) patients undergoing concurrent chemoradiotherapy (CCRT), negatively impacting their quality of life and treatment outcomes. Jishi Shuanghua Granules (JSG), a Traditional Chinese Medicine formulation, is widely used in clinical practice and has received positive feedback. However, high-quality evidence is still lacking. This study aims to evaluate the efficacy of JSG in reducing ARIE risk and severity and to explore its mechanisms through a multicenter, randomized, double-blind, placebo-controlled trial. Methods: A total of 240 stage III NSCLC patients scheduled to undergo definitive CCRT will be recruited and randomly assigned in a 1:1 ratio to either the JSG or placebo group. The primary efficacy endpoints will be the incidence rates of ARIE (≥Grade 1) and severe ARIE (SARIE, ≥Grade 3) based on the Radiation Therapy Oncology Group (RTOG) criteria. Secondary efficacy endpoints will include time to first occurrence of ARIE and SARIE, ARIE-related pain and dysphagia (assessed using the Numerical Rating Scale), quality of life (measured by the Functional Assessment of Cancer Therapy-Lung questionnaire), short-term lung cancer efficacy (objective response rate and disease control rate), and long-term outcomes (progression-free survival and overall survival). Additionally, the study will explore the mechanisms of JSG through multi-omics analyses, including lymphocyte subsets, inflammatory cytokines, oxidative stress markers, gut microbiota, and metabolomics. Discussion: If the trial meets its expected outcomes, this study will provide high-quality evidence supporting the use of JSG in preventing and treating ARIE. Furthermore, integrating multi-omics analyses will help elucidate the multi-target mechanisms of JSG, contributing to a more comprehensive evidence base. Clinical trial registration: http://itmctr.ccebtcm.org.cn/, identifier [ITMCTR2025000641].

Indexed as

concurrent chemoradiotherapynon-small cell lung cancerradiation-induced esophagitisTraditional Chinese Medicinetrial protocol

Identifiers

PMID42415804
PMCPMC13337399

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.